Paper916618
[Hemodynamic effects of sar1-ala8-angiotensin in patients with renovascular hypertension (author's transl)].
Philipp T and 2 others. Klin Wochenschr, 1977. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. [Hemodynamic effects of sar1-ala8-angiotensin in patients with renovascular hypertension (author's transl)]. Papers, record 916618. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/916618
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- [Hemodynamic effects of sar1-ala8-angiotensin in patients with renovascular hypertension (author's transl)].
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Angiotensin II | Major topic |
| Hemodynamics | Major topic |
| Hypertension, Renal | Major topic |
| Saralasin | Major topic |
| Adult | |
| Blood Pressure | |
| Diet, Sodium-Restricted | |
| Humans | |
| Middle Aged | |
| Renal Artery Obstruction | |
| Renin | |
| Vascular Resistance |
Source PubMed
References7
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 4140980 | Infusion of angiotensin-II analogue in two patients with unilateral renovascular hypertension. | Lancet | 1974 | https://conductscience.org/library/papers/4140980 | PubMed |
| 2 | 57453 | Renin dependency of blood-pressure. Analysis by angiotensin II antagonist P113 in hypertensive patients treated with salt depletion and propranolol. | Lancet | 1976 | https://conductscience.org/library/papers/57453 | PubMed |
| 3 | 1245602 | Blockade and stimulation of renal, adrenal, and vascular angiotensin II receptors with 1-Sar, 8-Ala angiotensin II in normal man. | J Clin Invest | 1976 | https://conductscience.org/library/papers/1245602 | PubMed |
| 4 | 235090 | Use of an angiotensin II antagonist (saralasin) in the recognition of "angiotensinogenic" hypertension;. | N Engl J Med | 1975 | https://conductscience.org/library/papers/235090 | PubMed |
| 5 | 14452128 | Hemodynamic and metabolic effects of angiotensin II during rest and exercise in normal healthy subjects. | Am Heart J | 1962 | https://conductscience.org/library/papers/14452128 | PubMed |
| 6 | 973974 | Agonist and antagonist effects of Sar1-ala8--angiotensin II in salt-loaded and salt-depleted normal man. | Br J Clin Pharmacol | 1976 | https://conductscience.org/library/papers/973974 | PubMed |
| 7 | 4760033 | Studies on the mechanism of aldosterone-induced hypertension in man. | Clin Sci Mol Med | 1973 | https://conductscience.org/library/papers/4760033 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AGT | 183 | PubTator's text mining | https://conductscience.org/library/genes/183 | NCBI Gene |
| REN | 5972 | PubTator's text mining | https://conductscience.org/library/genes/5972 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/916618
GET https://conductscience.org/api/papers/v1/916618/authors